



- (51) International Patent Classification:
A61K 9/14 (2006.01)
- (21) International Application Number:
PCT/US2014/063846
- (22) International Filing Date:
4 November 2014 (04.11.2014)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
61/901,949 8 November 2013 (08.11.2013) US
- (71) Applicant: **PRESIDENT AND FELLOWS OF HARVARD COLLEGE** [US/US]; 17 Quincy Street, Cambridge, Massachusetts 02138 (US).
- (72) Inventors: **UTECH, Stefanie**; 1350 Massachusetts Avenue, Cambridge, Massachusetts 02138 (US). **PRODANOVIC, Radivoje**; 1350 Massachusetts Avenue, Cambridge, Massachusetts 02138 (US). **AMSTAD, Esther**; 1350 Massachusetts Avenue, Cambridge, Massachusetts 02138 (US). **OSTAFE, Raluca**; 1350 Massachusetts Avenue, Cambridge, Massachusetts 02138 (US). **WEITZ, David A.**; 213 Green Road, Bolton, Massachusetts 01740 (US). **MAO, Angelo S.**; 1350 Massachusetts Avenue, Cambridge, Massachusetts 02138 (US). **MOONEY, David**

J.; 1350 Massachusetts Avenue, Cambridge, Massachusetts 02138 (US). **WILKING, Connie Chang**; 1350 Massachusetts Avenue, Cambridge, Massachusetts 02138 (US). **HUANAN, Wang**; 1350 Massachusetts Avenue, Cambridge, Massachusetts 02138 (US).

(74) Agents: **MADDEN, Robert B.** et al.; Schwegman, Lundberg & Woessner, P.A., P.O. Box 2938, Minneapolis, Minnesota 55402 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

[Continued on next page]

(54) Title: MICROPARTICLES, METHODS FOR THEIR PREPARATION AND USE




FIG. 1

(57) Abstract: The invention relates to microparticles comprising a crosslinked gel and methods for making and using same.





SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

Published:

— with international search report (Art. 21(3))

MICROPARTICLES, METHODS FOR THEIR PREPARATION AND USE

CLAIM OF PRIORITY

5 [0001] The Benefit of Priority is hereby claimed to U.S. Provisional Patent Application Serial Number 61/901,949, filed November 8, 2013, which is hereby incorporated by reference in its entirety.

BACKGROUND OF THE INVENTION

10 [0002] Microparticles formed from a crosslinked gel hold great potential for applications involving the encapsulation and release of actives for application in agriculture, encapsulation of food ingredients, health care, cosmetics, tissue engineering, sensors, optical components, coatings (*e.g.*, paints and pigments), additives, catalysis, and oil recovery. Despite their potential, it is very difficult to
15 obtain (hydro)gel microparticles having a defined shape and at least one dimension that is in the order of 50 μm or less. In addition, it is difficult to control the distribution of the crosslinking agent used to form the gel that makes up the microparticle and to guarantee for a reliable, reproducible, and structural homogenous gelation.

SUMMARY OF THE INVENTION

20 [0003] Embodiments of the present invention are directed to microparticles and methods for making such microparticles. Such microparticles are characterized by a high degree of monodispersity and structural homogeneity. The methods for forming such microparticles described herein
25 demonstrate a high degree of flexibility regarding size, shape, and morphology of the resulting microparticles. For example, microfluidic techniques can be used to prepare rods, crescents, hooks, as well as core-shell microparticles. Additionally, cells, including multiple (*e.g.*, biofilms), as well as single cells, can be encapsulated in the microparticles, which allows for long-term cell culture of
30 individual cells in an independent microenvironment. Further, there is an ability to grow identical colonies (*i.e.*, clones) of cells (*e.g.*, bacteria) using the microparticles of the embodiments of the present invention to encapsulate such cells.

[0004] The microparticles of the embodiments of the present invention can be used in a number of technological areas, including in the areas of pharmaceuticals, biotechnology, cosmetics, food additives, optical devices (*e.g.*, lenses) and sensors.

5 [0005] The ability to generate three dimensional cell systems has an enormous potential to increase the biological accuracy and physiological relevance of cell-based efficacy and toxicological tests in the pharmaceutical industry. Three-dimensional cell culture techniques not only offer excellent extracellular matrix and tissue mimics, but also allow for high-throughput
10 analysis and applications, especially in micron-sized systems. Hence, time and costs of relevant screening processes can be drastically reduced, resulting in a more efficient drug developing process. *See, e.g.*, Rimann *et al. Curr. Opin. Biotechnol.* 23: 803 (2012).

[0006] The microparticles of the embodiments of the present invention
15 can be used in drug delivery and drug release applications. By controlling the size, shape, and morphology, as well as the mechanical properties of the microparticles, release profiles and *in vivo* applicability can be improved and controlled.

[0007] Another area of possible applications for the microparticles of the
20 embodiments of the present invention is regenerative medicine and tissue engineering. Microparticles comprising cells can act as scaffolds or modules for transplants. Alginate, for example, has shown great potential in enhancing the regeneration and formation of bones, cartilage, skeletal muscles, nerves, pancreas, and blood vessels. Lee *et al. Prog. Polym. Sci.* 37: 106 (2012). Their
25 small size makes the presented cell-containing microparticles excellent candidates for injectable delivery vehicles in tissue engineering allowing for a tissue formation in a minimal invasive method. Park *et al. Macromol. Biosci.* 9: 895 (2009).

[0008] In the area of cosmetics, the microparticles of certain
30 embodiments of the present invention may be used, for example, to deliver stem cells in products designed to lift, protect or enhance the skin. *See, e.g.*, *Cosmetic and Pharmaceutical Applications of Polymers* (Gebelein *et al.* eds. Plenum 1991); and Schürch *et al. Phytochem. Rev.* 7: 599 (2008).

[0009] The microparticles of the embodiments of the present invention can also be used in the construction of lenses or sensor systems. By virtue of their mechanical, chemical, and morphological properties, in conjunction with the natural response to environmental conditions, renders the microparticles of the embodiments of the present invention useful in optical devices and sensors. Microgel Suspensions (Fernandez-Nieves eds., Wiley 2011).

[0010] In various embodiments, the invention relates to microparticles comprising: a crosslinked gel; wherein the microparticles have a coefficient of variation in the size distribution of the microparticles of from about 0.03 to about 0.05 and wherein the microparticles have at least one dimension measuring from about 5 μm to about 200 μm .

[0011] In various other embodiments, the invention relates to microparticles comprising: a Ca^{2+} -crosslinked alginate gel; wherein the microparticles have a coefficient of variation in the size distribution of the microparticles of from about 0.03 to about 0.05 and wherein the microparticles have at least one dimension measuring from about 5 μm to about 200 μm .

[0012] In still other embodiments, the invention relates to a method of forming the microparticles, the method comprising: forming microdroplets comprising one or more crosslinkable linear polysaccharides and one or more crosslinking agents; contacting the microdroplets with a crosslinking promoter to promote crosslinking of the one or more crosslinkable linear polysaccharides.

[0013] In yet other embodiments, the invention relates to a method of forming the microparticles, the method comprising: forming microdroplets comprising alginate and Ca^{2+} -EDTA; and contacting the microdroplets with a crosslinking promoter to promote crosslinking of the alginate.

BRIEF DESCRIPTION OF THE FIGURES

[0014] The drawings illustrate generally, by way of example, but not by way of limitation, various embodiments discussed in the present document.

[0015] FIG. 1 is a scheme showing the formation of alginate microparticles using a 50 μm polydimethylsiloxane (PDMS) dropmaker (panel a)) and microscopic images of resulting alginate microparticles in the size range of 15-50 μm after transfer into aqueous medium (panel b)).

[0016] FIG. 2 is a scheme showing the formation of alginate microparticles using a 50 μm PDMS dropmaker with integrated serpentine channel to alter the geometry of the formed microparticles (panel a)); microscopic images of cross-linked alginate microparticles (panel b)); and
5 microscopic images of non-spherical alginate microparticles after transfer into aqueous medium.

[0017] FIG. 3 is microscopic images of a 25 micrometer dropmaker (panel a)); and microscopic images of the resulting cell-containing microgels (panel b)) after breaking the emulsion with perfluoro-1-octanol (PFO).

10 [0018] FIG. 4 is microscopic images showing the formation of a water in water in oil (w/w/o) double emulsion using a two-dimensional microfluidic PDMS device (panel a)); and microscopic images of resulting microparticles with different alginate shell thicknesses (panel b)).

[0019] FIG. 5 is bright-field images (panels a) and d)) and fluorescent images (panel b) and e)) of alginate microparticles after transfer into an aqueous
15 medium; and a plot of diameter vs. frequency (panel c)).

[0020] FIG. 6 is microscopic images of cell-laden microgels formed using a 50 micrometer dropmaker (panels a) and b)); and a plot showing a Poisson distribution resulting in approximately 22 % of single-cell containing
20 droplets (panel c)).

[0021] FIG. 7 is microscopic images of proliferating cells inside individual alginate microparticles during culturing over the course of three weeks after addition of a live-stain (panels a)-c)). Living cells show a bright green fluorescence.

25 [0022] FIG. 8 is microscopic images of “Janus-type” binary microparticles. A fluorescently labeled alginate was used to identify the alginate-rich regions of the binary particle.

DETAILED DESCRIPTION OF THE INVENTION

[0023] Reference will now be made in detail to certain embodiments of
30 the disclosed subject matter, examples of which are illustrated in part in the accompanying drawings. While the disclosed subject matter will be described in conjunction with the enumerated claims, it will be understood that the

exemplified subject matter is not intended to limit the claims to the disclosed subject matter.

[0024] Values expressed in a range format should be interpreted in a flexible manner to include not only the numerical values explicitly recited as the limits of the range, but also to include all the individual numerical values or sub-ranges encompassed within that range as if each numerical value and sub-range were explicitly recited. For example, a range of “about 0.1% to about 5%” or “about 0.1% to 5%” should be interpreted to include not just about 0.1% to about 5%, but also the individual values (*e.g.*, 1%, 2%, 3%, and 4%) and the sub-ranges (*e.g.*, 0.1% to 0.5%, 1.1% to 2.2%, 3.3% to 4.4%) within the indicated range. The statement “about X to Y” has the same meaning as “about X to about Y,” unless indicated otherwise. Likewise, the statement “about X, Y, or about Z” has the same meaning as “about X, about Y, or about Z,” unless indicated otherwise.

[0025] In this document, the terms “a,” “an,” or “the” are used to include one or more than one unless the context clearly dictates otherwise. The term “or” is used to refer to a nonexclusive “or” unless otherwise indicated. In addition, it is to be understood that the phraseology or terminology employed herein, and not otherwise defined, is for the purpose of description only and not of limitation. Any use of section headings is intended to aid reading of the document and is not to be interpreted as limiting; information that is relevant to a section heading may occur within or outside of that particular section. Furthermore, all publications, patents, and patent documents referred to in this document are incorporated by reference herein in their entirety, as though individually incorporated by reference. In the event of inconsistent usages between this document and those documents so incorporated by reference, the usage in the incorporated reference should be considered supplementary to that of this document; for irreconcilable inconsistencies, the usage in this document controls.

[0026] In the methods described herein, the steps can be carried out in any order without departing from the principles of the invention, except when a temporal or operational sequence is explicitly recited. Furthermore, specified steps can be carried out concurrently unless explicit claim language recites that

they be carried out separately. For example, a claimed step of doing X and a claimed step of doing Y can be conducted simultaneously within a single operation, and the resulting process will fall within the literal scope of the claimed process.

5 [0027] The term “about” as used herein can allow for a degree of variability in a value or range, for example, within 10%, within 5%, or within 1% of a stated value or of a stated limit of a range.

[0028] The term “substantially” as used herein refers to a majority of, or mostly, as in at least about 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%,
10 99%, 99.5%, 99.9%, 99.99%, or at least about 99.999% or more.

[0029] Embodiments of the present invention relate to microparticles comprising a crosslinked gel, wherein the microparticles have at least one dimension measuring from about 1 μm to about 200 μm (*e.g.*, from about 5 μm to about 200 μm ; or from about 40 μm to about 200 μm). In some embodiments,
15 the microparticles have a coefficient of variation of from about 0.03 to about 0.05 (*e.g.*, from about 0.04 to about 0.05, or from about 0.03 to about 0.04). The term “coefficient of variation” refers to the standard deviation of the size distribution of the microparticles, assuming a Gaussian distribution, divided by the mean size. The coefficient of variation is a measure of the size polydispersity
20 observed for the contemplated microparticles. For non-spherical microparticles, the coefficient of variation is determined for each dimension of the particles, individually.

[0030] The microparticles may have any suitable dimensions and are, in some embodiments, substantially spherical such that the microparticles are
25 substantially microspheres. But the microparticles may also be non-spherical and of any suitable shape, including oblong, rod-, crescent- or hook-shaped. The microparticles can also be core-shell microparticles where the microparticles may have a liquid core and a solid shell; a gas core and a solid shell; or a solid core and a solid shell, all of which may referred to as core-shell microparticles.

30 [0031] In some embodiments, the microparticles of the embodiments of the present invention may have at least one dimension measuring less than 200 μm , less than 150 μm , less than 100 μm , less than 75 μm , less than 65 μm , less than 55 μm , less than 45 μm or less than 35 μm , with a lower bound of about 1

μm; from about 5 μm to about 15 μm; from about 10 μm to about 200 μm, from about 10 μm to about 100 μm, from about 10 μm to about 75 μm, from about 30 μm to about 75 μm, from about 30 μm to about 100 μm or from about 50 μm to about 100 μm. In some embodiments, the microparticles of the embodiments of the present invention are substantially spherical and have a diameter less than 200 μm, less than 150 μm, less than 100 μm, less than 75 μm, less than 65 μm, less than 55 μm, less than 45 μm or less than 35 μm, with a lower bound of about 10 μm; from about 10 μm to about 200 μm, from about 10 μm to about 100 μm, from about 10 μm to about 75 μm, from about 30 μm to about 75 μm, from about 30 μm to about 100 μm, from about 50 μm to about 100 μm or from about 40 μm to about 200 μm.

[0032] When the microparticles of the embodiments of the present invention are core-shell microparticles, the shell may have any suitable thickness. In some embodiments, the shell has a thickness of from about 200 nm to about 200 μm, about 200 nm to about 750 nm, from about 200 nm to about 1 μm, from about 750 nm to about 50 μm, from about 1 μm to about 50 μm, from about 25 μm to about 50 μm, from about 2 μm to about 10 μm or from about 2 μm to about 5 μm. In some embodiments, the thickness of the shell can be substantially uniform or it can be non-uniform. It should be appreciated that when the shell reaches a thickness that equals the diameter of the microparticle, then the microparticle will no longer be a core-shell microparticle and will instead be a microparticle.

[0033] In some embodiments, the microparticles of the embodiments of the present invention can comprise nanoparticles. In some embodiments, the nanoparticles can be homogeneously or inhomogeneously distributed throughout the microparticles. And in embodiments where the microparticles are core-shell microparticles, the nanoparticles can be homogeneously or inhomogeneously distributed throughout the core, the shell or both. In some embodiments, the nanoparticles can be magnetic nanoparticles (*e.g.*, iron oxide nanoparticles).

[0034] In some embodiments, the microparticles of the embodiments of the present invention can be core-shell microparticles and comprise a solid or a liquid core (*e.g.*, a substantially aqueous core comprising a substantially aqueous liquid). The solid core may be made of the same material as the shell or of a

different material than the shell. In some embodiments, the core is a liquid core. In some embodiments, the liquid core may be an aqueous core. When the liquid core is an aqueous core, it may be a water-only aqueous core or the water may comprise one or more materials dissolved in the water including salts (*e.g.*, NaCl and MgCl₂), buffers (*e.g.*, phosphate buffer), acids (*e.g.*, acetic acid and lactic acid), bases, cell growth medium, polymers (*e.g.*, poly(ethylene glycol), dextran), nutrients, encapsulants, polymers, nanoparticles or combinations thereof.

5
10 [0035] In some embodiments, the liquid core may be a non-aqueous core that can comprise, *e.g.*, an organic material including a solvent, a polymer, a dye, and the like.

[0036] In some embodiments, the core can be a solid core, a liquid core or a combination thereof. For example, the microparticles of the embodiments of the present invention may comprise a substantially solid core with liquid
15 “pockets” distributed throughout the substantially solid core. The “pockets” may be of a uniform size or the size of the “pockets” may be variable.

[0037] In other embodiments, the core can be a solid core, a liquid core or a combination thereof, wherein the core can comprise nanoparticles (*e.g.*, particles having at least one dimension having an average dimension of about 20
20 to about 500 nm, about 100 to about 500 nm, about 100 to about 300 nm or about 100 to about 200 nm) such as, but not limited to, magnetic nanoparticles such as iron oxide nanoparticles. In some embodiments, microparticles comprising such nanoparticles in their core can be useful in magnetic field-induced self-assembly of macrometer-sized constructs as engineered tissues for
25 regenerative medicine. In other embodiments, microparticles comprising such nanoparticles in their core can be useful as targeting delivery vehicles, such that a magnet or magnetic field placed at or near a target site (*e.g.*, organ or other tissue) would guide the microparticles comprising such nanoparticles to and concentrated at or near a target site at or near the magnet or magnetic field.
30 Among other things, anti-cancer drugs covalently or non-covalently attached to such nanoparticles could be delivered at or near a target site.

[0038] Microparticles containing nanoparticles smaller than 20 nm (*e.g.*, 1-20 nm) are also contemplated herein. Such nanoparticles (*e.g.*, functionalized

magnetic nanoparticles such as are known in the art) can be encapsulated or cross-linked within the crosslinked gel, crosslinked with the gel or combinations thereof.

[0039] In some embodiments, the aqueous or solid core and/or the shell
5 can comprise viruses, one or more cells (*e.g.*, mammalian cells, plant cells, bacteria, and combinations thereof) or proteins (*e.g.*, collagen and antibodies). The cells or proteins can be substantially within the microparticles; may protrude into the exterior of the microparticles (*e.g.*, through the shell of a core-shell microparticle); may protrude into the interior of the microparticles (*e.g.*, through
10 the shell of a core-shell microparticle and into the core); may protrude into the interior and the exterior of the microparticles (*e.g.*, traversing the shell of a core-shell microparticle). In some embodiments, the core comprises a single cell or protein.

[0040] The encapsulation of cells in microparticles of the embodiments
15 of the present invention may be advantageous for, *e.g.*, long-term (*e.g.*, twelve or more hours; fifteen or more hours; one or more days; five days to one month or more) cell culture of individual or multiple cells in an independent microenvironment. In addition, cells such as adherent cells can be cultured encapsulated in the microparticles of the embodiments of the present invention
20 because the microparticles of certain embodiments of the present invention provide a solid support that allows for a natural adherence and spreading of the cells within the microparticle. The microparticles can then be transferred to a cell culture medium or media where the cells within the microparticles are guaranteed a sufficient nutrient supply, given the solidified spheres can, in some
25 embodiments, be permeable to nutrients.

[0041] One advantage of having one or more cells or proteins protrude into the exterior of the microparticles, whether through the shell of a core-shell microparticle or a solid microparticle, is that the microparticle may have the propensity to form tissue-like assemblies. Briefly, by incorporating different cell
30 types in in defined regions of the core-shell particles (*e.g.*, encapsulation of one cell type into the core while a different cell type is incorporated into the shell of the particle) the balance of homotypic and heterotypic interactions can be controlled. *See, e.g.*, Khetani *et al. Nature Biotechnology* 26: 120-126 (2008).

[0042] In some embodiments, whether the core is a liquid core or a solid core, or combinations thereof, the core can comprise an active agent distributed in the core. In some embodiments, the active agent is a cell (*e.g.*, a plant stem cell), a pharmaceutical agent, an agrochemical agent or a food additive. *See, e.g.*,
5 Rimann *et al. Curr. Opin. Biotechnol.* 23: 803 (2012); Lee *et al. Prog. Polym. Sci.* 37: 106 (2012); and Microgel Suspensions (Fernandez-Nieves eds., Wiley 2011). Examples of pharmaceuticals include, but are not limited to antibiotics, antitussives, antihistamines, decongestants, alkaloids, mineral supplements, laxatives, antacids, anti-cholesterolemic, antiarrhythmics, antipyretics,
10 analgesics, appetite suppressants, expectorants, anti-anxiety agents, anti-ulcer agents, anti-inflammatory substances, coronary dilators, cerebral dilators, peripheral vasodilators, anti-infectives, psychotropics, antimaniacs, stimulants, gastrointestinal agents, sedatives, anti-diarrheal preparations, anti-anginal drugs, vasodilators, anti-hypertensive drugs, vasoconstrictors, migraine treatments,
15 antibiotics, tranquilizers, anti-psychotics, antitumor drugs, anticoagulants, antithrombotic drugs, hypotics, anti-emetics, anti-nauseants, anti-convulsants, neuromuscular drugs, hyper- and hypoglycemic spasmodics, uterine relaxants, mineral and nutritional additives, antiobesity drugs, anabolic drugs, erythropoietic drugs, antiasthmatics, cough suppressants, mucolytics, anti-uricemic drugs, mixtures thereof, and the like. Examples of agrochemicals
20 include, but are not limited to, chemical pesticides (such as herbicides, algicides, fungicides, bactericides, viricides, insecticides, acaricides, miticides, nematocides, and molluscicides), herbicide safeners, plant growth regulators, fertilizers and nutrients, gametocides, defoliant, desiccants, mixtures thereof and the like. Examples of food additives include, but are not limited to, caffeine, taste-masking agents, vitamins, minerals, color additives, herbal additives (*e.g.*,
25 echinacea or St. John's Wort), antimicrobials, preservatives, mixtures thereof, and the like.

[0043] In some embodiments, the microparticles of the embodiments of
30 the present invention may have pores. In some embodiments, the pores are distributed throughout the shell of core-shell microparticles of the embodiments of the present invention. The pores may have any suitable diameter and length. The pores may have, *e.g.*, a diameter ranging from about 1 nm to about 5 μm ,

e.g., from about 5 nm to about 5 μm , from about 5 nm to about 750 nm, from about 50 nm to about 500 nm or from about 50 nm to about 250 nm, from about 50 nm to about 250 nm or from about 5 nm to about 1 μm . The diameter of the pores may or may not be uniform within a single pore or across a multitude of
5 pores.

[0044] One of the functions of the pores is to serve as a conduit for any active agent to diffuse from the microparticle (*e.g.*, from the core; through the shell) into the environment surrounding the microparticles of the embodiments of the present invention. Those of skill in the art will recognize, however, that
10 the pores can also function as a conduit for materials located in the environment surrounding the microparticles of the embodiments of the present invention to diffuse into the microparticles. For example, in applications where one or more cells are located in the microparticles of the embodiments of the present invention, pores may play a key role as conduits for nutrients that are necessary
15 for cell growth within the microparticles.

[0045] In some embodiments, the microparticles of the embodiments of the present invention are degradable (*e.g.*, biodegradable). For example, the microparticles may be digestible by one or more enzymes or may degrade by hydrolysis. In other embodiments, the microparticles of the embodiments of the
20 present invention are non-degradable or partially degradable.

[0046] Microparticles of the embodiments of the present invention may be made of any suitable cross-linkable material that can be subsequently cross-linked via any suitable means for cross-linking, thereby yielding a crosslinked gel. Examples of suitable cross-linkable materials include, but are not limited to,
25 cross-linkable linear polysaccharides. In some embodiments, the cross-linkable material comprises homopolymeric blocks of (1-4)-linked β -D-mannuronate and α -L-guluronate. Non-limiting examples of cross-linkable materials that can be used to form the microparticles of the embodiments of the present invention include alginate, chitosan, curdlan, dextran, emulsan, a
30 galactoglucopolysaccharide, gellan, glucuronan, N-acetyl-heparosan, hyaluronic acid, indicant, kefiran, lentinan, levan, mauran, pullulan, scleroglucan, schizophyllan, stewartan, succinoglycan, xanthan, xylane, welan, starch, tamarind, tragacanth, guar gum, derivatized guar, gum ghatti, gum arabic, locust

bean gum, cellulose, hemicellulose, carboxymethyl cellulose, hydroxyethyl cellulose, carboxymethyl hydroxyethyl cellulose, hydroxypropyl cellulose, methyl hydroxyl ethyl cellulose, guar, hydroxypropyl guar, carboxy methyl guar, carboxymethyl hydroxypropyl guar or combinations thereof.

5 [0047] In some embodiments, the cross-linkable material can be derivatized to include, among other things, small molecules (*e.g.*, tyramine), oligonucleotides or oligopeptides (*e.g.*, polypeptides comprising the Arg-Gly-Asp recognition sequence, also known as “RGD”). The cross-linkable material can be derivatized before it is crosslinked or after it is crosslinked. In some
10 embodiments, the cross-linkable material is derivatized before it is crosslinked.

[0048] The cross-linkable material can be crosslinked via any suitable cross-linking mechanism. For example, the cross-linkable material can be crosslinked via covalent crosslinks, non-covalent crosslinks (*e.g.*, with the use of a crosslinking agent) or via a combination of covalent and non-covalent
15 crosslinks.


[0049] In some embodiments, the crosslinking agent comprises divalent cations including, but not limited to Ca^{2+} , Mg^{2+} , Ba^{2+} or combinations thereof. In some embodiments, the crosslinking agent is substantially homogeneously distributed in the microparticles of the embodiments of the present invention.

20 [0050] In some instances it may be advantageous for the divalent cations to be sequestered in any suitable way (*e.g.*, chelation) so that the crosslinking timing and rate can be controlled. For example, in some embodiments, the divalent cations may be chelated with any chelating agent suitable for chelating divalent cations including, but not limited to, ethylenediaminetetraacetic acid
25 (EDTA), ethylene glycol tetraacetic acid (EGTA), cyclohexane diamine tetraacetic acid (CDTA), citrate, and phosphate.

[0051] The microparticles of the embodiments of the present invention may be formed by a method comprising forming microdroplets (*e.g.*, microfluidically forming the microdroplets) comprising one or more
30 crosslinkable materials (*e.g.*, linear polysaccharides) and one or more crosslinking agents. In some embodiments, both components, the crosslinkable materials and the crosslinking agents are in liquid form, *e.g.*, as solutions in water or any suitable solvent. The resulting microdroplets can then be contacted

with a crosslinking promoter to crosslink the one or more crosslinkable materials (e.g., linear polysaccharides). The crosslinking promoter, in some embodiments, may be a change in the pH, a change in the temperature, a change in the ionic strength or combinations thereof. In some embodiments, the crosslinking promoter is a change in the pH. The change in the pH may be effected with an acid or a base, preferably an acid. In other embodiments, the crosslinking promoter is an ionic species (e.g., in solution) that is different from the crosslinking agent.

[0052] The acid may be any suitable acid and the ionic species may be any suitable ionic species, particularly an ionic species having a higher affinity for a chelating agent than the crosslinking agent. The acid and the ionic species cause a sufficient amount of chelated divalent cations to be sufficiently freed from chelation, thereby providing a sufficient amount of unchelated divalent cations to promote crosslinking. Scheme I, below, shows a schematic representation of this process using EDTA as a specific, non-limiting chelating agent and Ca^{2+} as a specific, non-limiting crosslinking agent.



Scheme I

[0053] Scheme I shows that there is an equilibrium between the chelated form of Ca^{2+} and the unchelated form of Ca^{2+} . The equilibrium may be driven to the left (i.e., to the unchelated form of Ca^{2+}) if a proton source (i.e., an acid, crosslinking promoter) is added. Enough acid may be added to generate a proton concentration that is, in turn, sufficient to generate a sufficient concentration of crosslinking agent (e.g., unchelated Ca^{2+}) to promote crosslinking.

[0054] In a specific, non-limiting example, where the cross-linkable material comprises alginate and the cross-linking agent comprises EDTA-chelated Ca^{2+} , above a certain pH, the binding affinity of EDTA for Ca^{2+} is higher than that of alginate. Thus, Ca^{2+} is bound by EDTA and cannot crosslink

the alginate. Shifting the pH toward a lower pH decreases the binding strength of EDTA to Ca^{2+} . Below a certain pH, the binding strength of alginate is higher than that of EDTA and thus, Ca^{2+} is complexed by alginate and serves as a crosslinking agent. It should be understood, however, that in some instances, depending on the cross-linkable material and/or the cross-linking agent comprising a chelated cation, the affinity of the chelating agent for the cation may be higher at lower pHs and lower at higher pHs, such that crosslinking is substantially prevented at lower pHs and promoted at higher pHs.

[0055] In some embodiments, the crosslinking promoter comprises an acid. The acid may be any suitable acid, including HCl and HF. In some embodiments, the acid that may be used as crosslinking promoters includes, but is not limited to, an organic acid. In some embodiments, organic acids include, but are not limited to, carboxylic acids such as C_2 - C_{10} carboxylic acids (*e.g.*, a C_2 - C_8 carboxylic acid, a C_2 - C_5 carboxylic acid, and a C_2 - C_4 carboxylic acid). Examples of C_2 - C_{10} carboxylic acids include, but are not limited to acetic acid, formic acid, benzoic acid, citric acid, oxalic acid, lactic acid or combinations thereof.

[0056] In some embodiments, the crosslinkable material can comprise functional groups that can be crosslinked via crosslinking mechanisms, in addition to crosslinking via a crosslinking agent. Thus, for example, one of the crosslinking mechanisms can be crosslinking via a crosslinking agent, but there can be at least one other crosslinking mechanism including covalent crosslinking via reactions between alcohols and carboxylic acids to form esters; reactions between amines and carboxylic acids to form amides; reactions between aldehydes and primary amines to form imines that can be reduced to secondary amines, reactions between alcohols and isocyanates to form carbamates; reactions between amines and isocyanates to give ureas; aryl-aryl coupling (*e.g.*, phenol-phenol coupling that is enzymatically catalyzed; *see Journal of Biomedical Materials Research Part A* 85: 345-351 (2008), which is incorporated herein by reference), or combinations thereof. Additional crosslinking mechanism can include radical and photochemical crosslinking mechanisms. In some embodiments, the primary crosslinking mechanism can be crosslinking via a crosslinking agent.

[0057] Physical crosslinking mechanisms are also contemplated herein.

[0058] The microparticles of the embodiments of the present invention may be used in methods for delivering an active agent to a subject (*e.g.*, a mammal, specifically a human) in need thereof or, in the case of agrochemicals, to an area (*e.g.*, a field or plot) in need thereof. The methods comprise (i) providing or obtaining one or more microparticle comprising an active agent; and (ii) delivering the microparticle to a location (*e.g.*, capillaries, skin, and eye) in a subject in need thereof or a location in an area in need thereof.

[0059] The microparticles may be delivered to the subject in need thereof or, in the case of agrochemicals, to an area in need thereof, by any suitable means. Such means for delivering the microparticles of the embodiments of the present invention to a subject in need thereof include, but are not limited to, oral, peroral, parenteral, intravenous, intraperitoneal, intradermal, subcutaneous, intramuscular, nasal, buccal, rectal or topical means, for example on the skin, mucous membranes or in the eyes. Means for delivering or depositing the microparticles of the embodiments of the present invention in an area in need thereof include, but are not limited to, spraying (*e.g.*, an aqueous suspension of the microparticles of the embodiments of the present invention).

[0060] In some embodiments, the microparticles of the embodiments of the present invention may be combined with other pharmaceutically acceptable or agronomically acceptable excipients. Such excipients may facilitate the incorporation of the microparticles of the embodiments of the present invention into dosage forms (*e.g.*, capsules, tablets, lozenges, and the like) or into, *e.g.*, pellets for agrochemical applications.

[0061] In some embodiments, when the microparticles of the embodiments of the present invention have a liquid core, and the core comprises an active agent, the microparticles can be ruptured by applying a suitable trigger. Such triggers include, but are not limited to mechanical force (*e.g.*, from the hand, when applied to the skin), ultrasound, oxidizing stress, osmotic stress, pH, phototriggers; reducing agents, enzyme/enzymatic triggers, temperature, magnetic fields, and combinations thereof.

[0062] In some embodiments, applying oxidizing stress to the microparticles includes contacting the microparticles with or exposing the

microparticles to an oxidizing agent. Suitable oxidizing agents include, but are not limited to, silver nitrate, potassium permanganate, sodium periodate, osmium tetroxide, peroxides, and sulfuric acid. An osmotic stress trigger includes, but is not limited to, exposing such microparticles to conditions where the ionic strength outside the microparticles is substantially less than the ionic strength inside the microparticles (*i.e.*, in the core). An example of such a situation includes microparticles containing a high salt (*e.g.*, CaCl₂) concentration (*e.g.*, from about 1 to about 2 M salt) in the core being exposed to a significantly lower salt (*e.g.*, about 0 to about 0.5 M) concentration outside the microparticles or vice versa.

[0063] In various other embodiments, the invention relates to a system comprising one or more microparticles of the embodiments of the present invention and one or more cells encapsulated in the one or more microparticles. In some embodiments, each microparticle comprises more than one cell. In other 15 embodiments, each microparticle comprises a single cell.

[0064] The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various 20 modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those of ordinary skill in the art, and that such modifications and variations are 25 considered to be within the scope of this invention as defined by the appended claims.

Examples

[0065] The present invention can be better understood by reference to the following examples which are offered by way of illustration. The present 30 invention is not limited to the examples given herein.

Example 1: Solid Particles

[0066] Using droplet-based microfluidics, monodisperse droplets of a calcium-EDTA/alginate mixture can be produced with a precise size control in

the micrometer regime. See FIG. 1, which contains two panels a) and b). Panel a) is a scheme showing the formation of alginate microparticles using a 50 μm PDMS dropmaker (left: channel outline, right: microscopic image of crossjunction (4x)). The liquid microdroplets contain Ca-EDTA (100 mM, pH 7.0)/alginate (2.0 % w/v) (1:1). The microdroplets are solidified into microparticles by diffusion of acetic acid present in the outer phase (1.0 % PFPE-PEG block-copolymer surfactant (Holtze *et al. Lab Chip* 8: 1632 (2008)) in HFE7500 (3M), and 1 $\mu\text{L}/\text{mL}$ acetic acid) into the drop. Panel b) of FIG. 1 shows microscopic images of resulting alginate microparticles. The particle size can be controlled by adapting the flow rates of the system (scale bars 20 μm).

[0067] The gels shown in Figure 1b are produced by using two different dropmakers: the first six images from the left: 25 μm dropmaker, the last six images: 50 μm dropmaker. The flow rate of the inner phase (alginate/EDTA-complex) was kept at 50 $\mu\text{L}/\text{h}$. The flow rate of the oil phase was varied in the following order (from left image to right): 1000, 800, 600, 400, 200, 100 $\mu\text{L}/\text{h}$; 1000, 800, 600, 400, 200, 100 $\mu\text{L}/\text{h}$.

[0068] The gelation of the drops can either be induced by diffusion of acetic acid into the drop or by addition of acid-generating compounds into the drops like lactones, specific example is gluconolactone. By controlling the gelation rate, as well as the channel geometry, spherical as well as non-spherical particles are accessible. Rapid gelation of alginate leads to a solidification of the liquid alginate drops inside the microfluidic channel allowing for control over the shape of the cross-linked alginate particles through the design of the channel geometry. Therefore, a variety of non-spherical particles can be created including rods, hooks, crescents, for example. See FIG. 2, which contains three panels a)-c). Panel a) is a scheme showing the formation of alginate microparticles using a 50 μm PDMS dropmaker (left: channel outline, right: microscopic image of crossjunction (4x)). The liquid microdroplets contain Ca-EDTA (100 mM, pH 7.0)/alginate (2.0 % w/v) (1:1). The microdroplets are solidified into microparticles by diffusion of acetic acid present in the outer phase (1.0 % PFPE-PEG block-copolymer surfactant (Holtze *et al. Lab Chip* 8: 1632 (2008)) in HFE7500 (3M), and 1 $\mu\text{L}/\text{mL}$ acetic acid) into the drop. Panel b) of FIG. 2 shows microscopic images of cross-linked alginate microparticles in

the channel outlet (4x). The geometry of the rod-like structure can be influenced by controlling the flow rates during drop formation (flow rates inner/outer phase (in $\mu\text{L/h}$) from left to right: 50/150, 50/400, 50/800). Panel c) of FIG. 2 shows non-spherical alginate microparticles obtained from different flow rates using the channel geometry shown in panel a) (flow rates inner/outer phase (in $\mu\text{L/h}$) from left to right: 150/200, 150/500, 150/700) (scale bars 25 μm).

[0069] The mechanical properties of the gels can also be controlled by the concentration and chemical nature of the alginates (*e.g.*, molecular weights and β -D-mannuronate (M)/ α -L-guluronate (G) ratios/lengths). To enhance the stability of the microparticles, a combination of physical and chemical cross-linking can be performed by the incorporation of covalently cross-linkable groups, *e.g.*, phenol units. *See, e.g., Journal of Biomedical Materials Research Par A 85: 345-351 (2008)*, which is incorporated by reference.

[0070] The developed approach is compatible with microfluidic methods and drop formation techniques and can be combined with a variety of microfluidic applications as cell encapsulation, high-throughput analysis or materials production.

Example 2: Cell-encapsulation

[0071] Cell-containing microparticles can be generated by combining the described method with microfluidic cell encapsulation techniques. *See Clausell-Tormos et al. Chemistry & Biology 15: 427 (2008)* and *Köster et al. Lab Chip 8: 1110 (2008)*. After gelation the resulting cell-laden microparticles can be transferred into aqueous cell culture medium without losing the integrity of the generated microenvironment. Any surfactant present when the microparticles are formed may be removed by addition of a suitable agent such as perfluoro-1-octanol (PFO), followed by subsequent centrifugation, removal of the oil phase, and re-dispersion of the microparticles in cell culture medium.

[0072] Single, as well as multiple biological entities, *e.g.*, mammalian and plant cells, proteins or peptides (*e.g.*, collagen, RGD, antibodies), bacteria, viruses, can be incorporated into one microparticles of the embodiments of the present invention allowing for long-term biological screenings, single-cell analysis, and culturing in independent microenvironments. *See FIG. 3*, which contains two panels a) and b). Panel a) shows microscopic images of a 25

micrometer dropmaker (inner phase: Ca-EDTA (100 mM, pH 7.0)/alginate (2.0 % w/v) (1:1); outer phase: 1.0 % PFPE-PEG block-copolymer surfactant (Holtze *et al. Lab Chip* 8: 1632 (2008)) in HFE7500 (3M), and 1 μ L/mL acetic acid) (4x). Panel b) in FIG. 3 is microscopic images of the resulting cell-containing
5 microgels (carrying single or multiple cells) after breaking the emulsion with PFO, centrifugation, and transfer to aqueous medium (scale bars: 25 micrometer).

[0073] The solid nature of the microparticle can also be used as scaffold or solid-support for adherent cells and thus mimics conditions found *in vivo* or in
10 bulk cell culture experiments.

[0074] The encapsulated cells show good viability and proliferation for several weeks. In analogy to experiments with liquid cell-laden drops, the cell-containing microparticles can individually be manipulated (sorting, screening, picoinjection, etc.). See Schmitz *et al., Lab Chip* 9: 44 (2009); Abate *et al., PNAS* 107: 19163 (2010); Agresti *et al., PNAS* 107: 4004 (2010); Baret, *Lab Chip* 9: 1850 (2009); and Guo *et al., Lab Chip* 12: 2146 (2012).
15

[0075] Concerning long-term cell culture, a homogeneous gelation which is directly correlated with the mechanical properties of the corresponding gel may impact acceptable experimental reproducibility. It has been shown that the
20 proliferation of cells may be influenced by the mechanical properties of their environment and is therefore mechanical properties is an important factor for screening and cell culture applications. See Klein *et al., Current Biology* 19: 1511 (2009); and Khatiwala *et al., Am. J. Physiol. Cell Physiol.* 290: C1640 (2006).

25 **Example 3: Core-shell particles and capsules**

[0076] Core-shell geometries and capsules can be assembled as any suitable emulsion, including, but not limited to, water-in-water-in-oil (w/w/o), o/w/o, and w/o/w double emulsions. See FIG. 4, which contains two panels a) and b). Panel a) is microscopic images showing the formation of a water in water
30 in oil (w/w/o) double emulsion using a two-dimensional microfluidic PDMS device (inner phase: 20 % PEG, middle phase: Ca-EDTA (100 mM, pH 7.0)/alginate (2% w/v) (1:1), outer phase: 1.0 % PFPE-PEG block-copolymer surfactant (Holtze *et al. Lab Chip* 8: 1632 (2008)) in HFE7500 (3M), and 1

μL/mL acetic acid (4x)). The Ca-EDTA/alginate shell is solidified by diffusion of acetic acid present in the outer phase into the drop. Panel b) of FIG. 4 is microscopic images of resulting alginate microparticles with different shell thicknesses (not density matched) obtained by different flow rates (flow rates
5 inner/middle/outer phase (in μL/h) from left to right: 20/60/1000, 60/20/1000) (scale bars: 25 μm).

[0077] If alginate is used as an outer phase, homogenous capsules can be assembled and their size and shell thickness can be tuned with the flow rates and device geometry. In analogy to the solid particles described in Example 1, the
10 microparticles can be transferred into aqueous media after alginate is gelled.

[0078] For w/w/o emulsions alginate forms the middle phase and the oil phase forms the outer phase.

[0079] Core-shell particles of a great variety of materials can be formed by changing the composition of the inner phase. For example, the use of alginate
15 solutions of different concentrations, properties, and/or compositions (*e.g.*, molecular weights, M/G-ratios, ratio of concentration of alginate to Ca²⁺, and any additional degree of crosslinking, in cases where the alginate has been, *e.g.*, covalently crosslinked to some/any extent) lead to alginate/alginate core-shell particles exhibiting a gradient in stiffness. Thus, for example, a lower molecular
20 weight alginate will result in a “softer” microparticle. Also, when gels are made from an alginate rich in guluronic acid residues, higher moduli are obtained compared to gels made from alginates less enriched in G residues. While not being bound by any particular theory, it is believed that the reason for this behavior is that high-G gels, with their long G-blocks and their short elastic segments become more of a stiff open and static network compared to the more
25 dynamic and entangled network structure of the low-G gels with their relative long elastic segments. *See Inter. J. Biol. Macromol. 21: 47-55 (1997).*

[0080] In analogy to alginate hydrogel drops, cells can also be loaded into these capsules and core-shell particles.

30 [0081] Additionally, the formation of shells thicknesses in the nanometer range as well as the generation of water in water in water (w/w/w) emulsions may be possible. Triple or higher order emulsions are also possible.

Example 4

[0082] FIG. 5 contains bright-field (panels a)) and fluorescent (panel b)) images of alginate microparticles after transfer into an aqueous medium. The images reflect the high monodispersity of the spherical particles as shown in panel c). The high-magnification images (panel d) = bright-field; and panel e) = fluorescent) reveals the homogeneous structure of the alginate microsphere. Panel f) contains bright-field images of homogeneous alginate microgels with 15, 21, 28 and 39 μm in diameter. All scale bars are 50 μm .

Example 5

10 [0083] Cell-laden microgels were formed using a 50 micrometer dropmaker. *See* FIG. 6 panel a). During the drop formation process, cells are encapsulated and the resulting microgels are collected at the channel outlet. *See* FIG. 6, panel b). Single-cell containing droplets are indicated by white arrows and boxes in panels a) and b), respectively. The encapsulation process follows the Poisson distribution resulting in approximately 22 % of single-cell containing droplets. *See* panel c). All scale bars are 100 μm .

Example 6

[0084] Cell-containing microparticles were observed directly after encapsulation and during culture over the period of 366 h. *See* FIG. 7, panel a). Representative images of proliferating cells inside individual alginate microparticles after addition of a live stain. *See* FIG. 7, panel b). Living cells exhibit green fluorescence. *See* FIG. 7, panel b), lower row. About 80 % of the cells were alive directly after encapsulation and transfer into cell culture medium. The cells show a natural proliferation inside the droplets under maintenance of their spherical shape. After three weeks of encapsulation the cell viability was determined to be 55% . All scale bars are 25 μm .

Example 7: Binary Microparticles

[0085] In some embodiments, the microparticles can be “Janus-type” binary microparticles, where the microparticle is divided into two separate regions that may be made of the same material. In some embodiments, the microparticle is divided into two separate regions (*e.g.*, compartments) that may be made of a different material. *See, e.g.*, FIG. 8. For example, in some embodiments, the two separate regions can contain two compartments, each

compartment comprising different materials where one compartment can comprise a single or a plurality of suitable magnetic nanoparticles (*e.g.*, iron oxide nanoparticles) and the other compartment can comprise no magnetic nanoparticles. And in embodiments where the two separate regions contain two
5 compartments, each compartment comprising the same material, both compartments can comprise a single or a plurality of suitable magnetic nanoparticles (*e.g.*, iron oxide nanoparticles).

[0086] In other embodiments, each compartment can comprise at least one cell, where the cell or cells in each compartment can be the same or the cell
10 or cells in a first compartment is different from the cell or cells in a second compartment. Even if the at least one cell is the same in each compartment, the at least one active agent may be present at a different cell concentration in each compartment. Or if the at least one cell is different in each compartment, the two different at least one cells may also be present at a different cell concentration.

[0087] In other embodiments, each compartment can comprise at least one active agent, where the active agent or agents in each compartment can be
15 the same or the active agent or agents in a first compartment is different from the active agent or agents in a second compartment. Even if the at least one active agent is the same in each compartment, the at least one active agent may be present at a different concentration in each compartment. Or if the at least one
20 active agent is different in each compartment, the two different at least one active agents may also be present at a different concentration.

[0088] In some embodiments, binary microparticles may be prepared microfluidically using the same microfluidic apparatus used to make core-shell
25 microparticles herein by mismatching the osmotic pressure in the inner phase (*e.g.*, a PEG phase) and the middle phase (*e.g.*, an alginate-containing phase) in a w/w/o double emulsion. A solution containing an EDTA-calcium complex is added to the alginate phase but not to the inner phase. After polymerization of the alginate phase, the core-shell microparticle phase-separate into two distinct
30 domains. Ternary and higher order particle architectures can also be envisioned.

[0089] The present invention provides for the following exemplary embodiments, the numbering of which is not to be construed as designating levels of importance:

[0090] Embodiment 1 relates to microparticles comprising: a crosslinked gel; wherein the microparticles have a coefficient of variation in the size distribution of the microparticles of from about 0.03 to about 0.05 and wherein the microparticles have at least one dimension measuring from about 5 μm to
5 about 200 μm .

[0091] Embodiment 2 relates to the microparticles of Embodiment 1, wherein the crosslinked gel comprises one or more crosslinked linear polysaccharides.

[0092] Embodiment 3 relates to the microparticles of Embodiment 2,
10 wherein the crosslinked linear polysaccharide comprises alginate, chitosan, curdlan, dextran, emulsan, a galactoglucopolysaccharide, gellan, glucuronan, N-acetyl-heparosan, hyaluronic acid, indicant, kefiran, lentinan, levan, mauran, pullulan, scleroglucan, schizophyllan, stewartan, succinoglycan, xanthan, xylane, welan, starch, tamarind, tragacanth, guar gum, derivatized guar, gum ghatti, gum
15 arabic, locust bean gum, cellulose, hemicellulose, carboxymethyl cellulose, hydroxyethyl cellulose, carboxymethyl hydroxyethyl cellulose, hydroxypropyl cellulose, methyl hydroxyl ethyl cellulose, guar, hydroxypropyl guar, carboxy methyl guar, carboxymethyl hydroxypropyl guar or combinations thereof.

[0093] Embodiment 4 relates to the microparticles of Embodiment 2,
20 wherein the crosslinked linear polysaccharide comprises crosslinked alginate.

[0094] Embodiment 5 relates to the microparticles of Embodiment 2, wherein the crosslinked linear polysaccharide comprises a crosslinking agent.

[0095] Embodiment 5A relates to the microparticles of Embodiment 5, wherein the crosslinking agent is substantially homogenously distributed in the
25 microparticle.

[0096] Embodiment 5B relates to the microparticles of Embodiment 5, wherein the microparticles are core-shell microparticles or binary or higher order microparticles; and the crosslinking agent is substantially homogenously distributed in the core, the shell, or the core and the shell of core-shell
30 microparticles; or, when the microparticles are binary or higher order microparticles, in one or more (preferably all) of the microparticles comprised in the binary or higher order microparticles.

- [0097] Embodiment 6 relates to the microparticles of Embodiment 5, wherein the crosslinking agent comprises divalent cations.
- [0098] Embodiment 7 relates to the microparticles of Embodiment 6, wherein the divalent cations comprise Ca^{2+} , Mg^{2+} , Ba^{2+} or combinations thereof.
- 5 [0099] Embodiment 8 relates to the microparticles of Embodiments 1-7, wherein the microparticles are substantially spherical.
- [00100] Embodiment 9 relates to the microparticles of Embodiments 1-7, wherein the microparticles are rod-, crescent- or hook-shaped.
- [00101] Embodiment 10 relates to the microparticles of Embodiments 8 or
10 9, wherein the microparticles are core-shell microparticles.
- [00102] Embodiment 11 relates to the microparticles of Embodiments 8 or 9, wherein the microparticles are binary microparticles.
- [00103] Embodiment 12 relates to the microparticles of Embodiment 10, wherein the core is a liquid core, a solid core or a gas core.
- 15 [00104] Embodiment 13 relates to the microparticles of Embodiment 12, wherein the core is an aqueous core.
- [00105] Embodiment 14 relates to the microparticles of Embodiment 10, wherein the microparticles comprise a liquid core and a solid shell; a gas core and a solid shell; or a solid core and a solid shell.
- 20 [00106] Embodiment 15 relates to the microparticles of Embodiment 10, wherein the core and/or the shell comprises one or more cells. In another embodiment, at least one of the core and the shell comprises one or more cells.
- [00107] Embodiment 16 relates to the microparticles of Embodiments 1-5, 5A, 5B, and 6-15, wherein the microparticles comprise an active agent.
- 25 [00108] Embodiment 17 relates to the microparticles of Embodiment 16, wherein the active agent is a pharmaceutical, an agrochemical or a food additive.
- [00109] Embodiment 18 relates to the microparticles of Embodiments 1-5, 5A, 5B, and 6-17, wherein the microparticles are degradable, non-degradable or partially degradable.
- 30 [00110] Embodiment 19 relates to the microparticles of Embodiments 1-5, 5A, 5B, and 6-18, wherein the microparticles comprise pores.
- [00111] Embodiment 20 relates to microparticles comprising: a Ca^{2+} -crosslinked alginate gel; wherein the microparticles have a coefficient of

variation in the size distribution of the microparticles of from about 0.03 to about 0.05 and wherein the microparticles have at least one dimension measuring from about 5 μm to about 200 μm .

5 [00112] Embodiment 21 relates to a method of forming the microparticles of Embodiment 1, the method comprising: forming microdroplets comprising one or more crosslinkable linear polysaccharides and one or more crosslinking agents; contacting the microdroplets with a crosslinking promoter to promote crosslinking of the one or more crosslinkable linear polysaccharides.

10 [00113] Embodiment 22 relates to the method of Embodiment 21, wherein the crosslinking agent does not substantially crosslink the one or more crosslinkable linear polysaccharides in an initial state, but, upon contacting with the crosslinking promoter, crosslinks the one or more crosslinkable linear polysaccharides in a second state.

15 [00114] Embodiment 23 relates to the method of Embodiment 22, wherein the first state comprises a sequestered state of the one or more crosslinking agents and the second state comprises an unsequestered state of the one or more crosslinking agents.

20 [00115] Embodiment 24 relates to the method of Embodiments 21-23, wherein the crosslinking agent is substantially homogenously distributed in the microparticle.

[00116] Embodiment 25 relates to the method of Embodiment 21-24, wherein said forming comprises microfluidically forming the microdroplets.

[00117] Embodiment 26 relates to the method of Embodiment 21-25, wherein the crosslinking agent comprises divalent cations.

25 [00118] Embodiment 27 relates to the method of Embodiment 26, wherein the divalent cations comprise Ca^{2+} , Mg^{2+} , Ba^{2+} or combinations thereof.

[00119] Embodiment 28 relates to the method of Embodiment 26, wherein the divalent cations are sequestered.

30 [00120] Embodiment 29 relates to the method of Embodiment 28, wherein the sequestered divalent cations are chelated.

[00121] Embodiment 30 relates to the method of Embodiment 29, wherein the chelated divalent cations comprise Ca^{2+} -EDTA.

- [00122] Embodiment 31 relates to the method of Embodiments 21-30 , wherein said crosslinking promoter comprises a change in the pH, a change in the temperature, a change in the ionic strength or combinations thereof.
- [00123] Embodiment 32 relates to the method of Embodiment 31, wherein
5 said crosslinking promoter comprises a change in the pH.
- [00124] Embodiment 33 relates to the method of Embodiment 32, wherein the change in the pH is effected with an acid.
- [00125] Embodiment 34 relates to the method of Embodiment 33, wherein the acid comprises a carboxylic acid.
- 10 [00126] Embodiment 35 relates to the method of Embodiment 34, wherein the carboxylic acid comprises a C₂-C₁₀-carboxylic acid.
- [00127] Embodiment 36 relates to the method of Embodiment 35, wherein the C₂-C₁₀-carboxylic acid comprises acetic acid, formic acid, benzoic acid, citric acid, oxalic acid, lactic acid or combinations thereof.
- 15 [00128] Embodiment 37 relates to the method of Embodiment 36, wherein the divalent cations are sequestered and the crosslinking promoter causes sequestered divalent cations to be sufficiently freed from sequestration such that crosslinking of the one or more crosslinkable linear polysaccharides is promoted.
- [00129] Embodiment 38 relates to a method of forming the microparticles
20 of Embodiment 20, the method comprising: forming microdroplets comprising alginate and Ca²⁺-EDTA; and contacting the microdroplets with a crosslinking promoter to promote crosslinking of the alginate.
- [00130] Embodiment 39 relates to a method for delivering one or more microparticles of Embodiments 1-5, 5A, 5B, and 6-20, or microparticles made
25 according to the method of Embodiments 21-38, to a location in a subject in need thereof or to an area in need thereof, the method comprising (i) providing or obtaining one or more microparticle comprising an active agent; and (ii) delivering the microparticle to a location in a subject in need thereof or a location in an area in need thereof.
- 30 [00131] Embodiment 40 relates to a system comprising one or more microparticles of Embodiments 1-5, 5A, 5B, and 6-20, or microparticles made according to the method of Embodiments 21-38, and one or more cells

encapsulated in the one or more microparticles of Embodiments 1-5, 5A, 5B, and 6-20, or microparticles made according to the method of Embodiments 21-38.

[00132] Embodiment 41 relates to the use of the microparticles of Embodiments 1-5, 5A, 5B, and 6-20, or microparticles made according to the method of Embodiments 21-38, in pharmaceuticals, medical, biotechnology, cosmetics, food additives, optical devices, sensors or combinations thereof.

[00133] Embodiment 42 relates to the microparticles Embodiments 1-5, 5A, 5B, and 6-19, wherein the microparticles comprise magnetic nanoparticles.

CLAIMS

What is claimed is:

1. Microparticles comprising:
5 a crosslinked gel;
 wherein the microparticles have a coefficient of variation in the size
 distribution of the microparticles of from about 0.03 to about 0.05 and
 wherein the microparticles have at least one dimension measuring from
 about 5 μm to about 200 μm .
10
2. The microparticles of claim 1, wherein the crosslinked gel comprises one
 or more crosslinked linear polysaccharides.
3. The microparticles of claim 2, wherein the crosslinked linear
15 polysaccharide comprises alginate, chitosan, curdlan, dextran, emulsan, a
 galactoglucopolysaccharide, gellan, glucuronan, N-acetyl-heparosan,
 hyaluronic acid, indicant, kefiran, lentinan, levan, mauran, pullulan,
 scleroglucan, schizophyllan, stewartan, succinoglycan, xanthan, xylane,
 welan, starch, tamarind, tragacanth, guar gum, derivatized guar, gum
20 ghatti, gum arabic, locust bean gum, cellulose, hemicellulose,
 carboxymethyl cellulose, hydroxyethyl cellulose, carboxymethyl
 hydroxyethyl cellulose, hydroxypropyl cellulose, methyl hydroxyl ethyl
 cellulose, guar, hydroxypropyl guar, carboxy methyl guar,
 carboxymethyl hydroxylpropyl guar or combinations thereof.
25
4. The microparticles of claim 2, wherein the crosslinked linear
 polysaccharide comprises crosslinked alginate.
5. The microparticles of claim 2, wherein the crosslinked linear
30 polysaccharide comprises a crosslinking agent.
6. The microparticles of claim 5, wherein the crosslinking agent comprises
 divalent cations.


7. The microparticles of claim 6, wherein the divalent cations comprise Ca^{2+} , Mg^{2+} , Ba^{2+} or combinations thereof.
- 5 8. The microparticles of claim 1, wherein the microparticles are substantially spherical.
9. The microparticles of claim 1, wherein the microparticles are rod-, crescent- or hook-shaped.
- 10 10. The microparticles of claim 8 or 9, wherein the microparticles are core-shell microparticles.
11. The microparticles of claim 8 or 9, wherein the microparticles are binary
15 microparticles.
12. The microparticles of claim 10, wherein the core is a liquid core, a solid core or a gas core.
- 20 13. The microparticles of claim 12, wherein the core is an aqueous core.
14. The microparticles of claim 10, wherein the microparticles comprise a liquid core and a solid shell; a gas core and a solid shell; or a solid core and a solid shell.
- 25 15. The microparticles of claim 10, wherein at least one of the core and the shell comprises one or more cells.
16. The microparticles of claim 1, wherein the microparticles comprise an
30 active agent.
17. The microparticles of claim 16, wherein the active agent is a pharmaceutical, an agrochemical or a food additive.
- 35 18. The microparticles of claim 1, wherein the microparticles comprise magnetic nanoparticles.

19. The microparticles of claim 1, wherein the microparticles are degradable, non-degradable or partially degradable.
- 5 20. The microparticles of claim 1, wherein the microparticles comprise pores.
21. Microparticles comprising:
a Ca²⁺-crosslinked alginate gel;
- 10 wherein the microparticles have a coefficient of variation in the size distribution of the microparticles of from about 0.03 to about 0.05 and wherein the microparticles have at least one dimension measuring from about 5 μm to about 200 μm.
- 15 22. A method of forming the microparticles of claim 1, the method comprising:
forming microdroplets comprising one or more crosslinkable linear polysaccharides and one or more crosslinking agents;
contacting the microdroplets with a crosslinking promoter to promote
20 crosslinking of the one or more crosslinkable linear polysaccharides.
23. The method of claim 22, wherein the crosslinking agent does not substantially crosslink the one or more crosslinkable linear polysaccharides in an initial state, but, upon contacting with the
25 crosslinking promoter, crosslinks the one or more crosslinkable linear polysaccharides in a second state.
24. The method of claim 23, wherein the first state comprises a sequestered state of the one or more crosslinking agents and the second state
30 comprises an unsequestered state of the one or more crosslinking agents.
25. The method of claim 23, wherein the crosslinking agent is substantially homogeneously distributed in the microparticle.

26. The method of claim 22, wherein said forming comprises microfluidically forming the microdroplets.
27. The method of claim 22, wherein the crosslinking agent comprises
5 divalent cations.
28. The method of claim 27, wherein the divalent cations comprise Ca^{2+} , Mg^{2+} , Ba^{2+} or combinations thereof.
- 10 29. The method of claim 27, wherein the divalent cations are sequestered.
30. The method of claim 29, wherein the sequestered divalent cations are chelated.
- 15 31. The method of claim 30, wherein the chelated divalent cations comprise Ca^{2+} -EDTA.
32. The method of claim 22, wherein said crosslinking promoter comprises a change in the pH, a change in the temperature, a change in the ionic
20 strength or combinations thereof.
33. The method of claim 32, wherein said crosslinking promoter comprises a change in the pH.
- 25 34. The method of claim 33, wherein the change in the pH is effected with an acid.
35. The method of claim 34, wherein the acid comprises a carboxylic acid.
- 30 36. The method of claim 35, wherein the carboxylic acid comprises a C_2 - C_{10} -carboxylic acid.
37. The method of claim 36, wherein the C_2 - C_{10} -carboxylic acid comprises acetic acid, formic acid, benzoic acid, citric acid, oxalic acid, lactic acid
35 or combinations thereof.

38. The method of claim 27, wherein the divalent cations are sequestered and the crosslinking promoter causes sequestered divalent cations to be sufficiently freed from sequestration such that crosslinking of the one or more crosslinkable linear polysaccharides is promoted.
39. A method of forming the microparticles of claim 21, the method comprising:
forming microdroplets comprising alginate and Ca^{2+} -EDTA; and
contacting the microdroplets with a crosslinking promoter to promote crosslinking of the alginate.
40. A method for delivering one or more microparticles of claim 1 to a location in a subject in need thereof or to an area in need thereof, the method comprising (i) providing or obtaining one or more microparticle comprising an active agent; and (ii) delivering the microparticle to a location in a subject in need thereof or a location in an area in need thereof.
41. A system comprising one or more microparticles of claim 1 and one or more cells encapsulated in the one or more microparticles.
42. The use of the microparticles of claim 1 in pharmaceuticals, medical, biotechnology, cosmetics, food additives, optical devices, sensors or combinations thereof.

a)




b)




FIG. 1

a)



b)



c)




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG. 8

INTERNATIONAL SEARCH REPORT

INTERNATIONAL APPLICATION NO.

PCT/US 14/63846

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - A61K 9/14 (2015.01)

CPC - A61K 9/1694; A61K 9/1617; A61K 9/1652

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC(8) - A61K 9/14 (2015.01)

CPC - A61K 9/1694; A61K 9/1617; A61K 9/1652

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
UC - 424/489

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Minesoft Patbase, Google Scholar, Microparticle*, microparticulat*, particl*, bead*, microbead*, droplet*, microdroplet*, microspher*, microgel*, rod, crescent, hook, alginate*, guar, gum, chitosan, curdlan, dextran, cellulose, polysaccharides, binary, divalent*, bivalent*, polyvalent*, multivalent*, Ca, Ba, Sr, Mg, crosslink*, cross-link*, ?coe

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X ----- Y	US 2013/0064862 A1 (Weitz et al.) 14 March 2013 (14.03.2013) entire document especially para [0042]; [[0043]; [0054]; [0071]; [0086]-[0090]; [0094]	1-8, 10, 12-17, 19-21, 41, 42
Y	US 2013/0004522 A1 (Dvir et al.) 03 January 2013 (03.01.2013) para [0039]	9, 11, 18
Y	US 2013/0004522 A1 (Dvir et al.) 03 January 2013 (03.01.2013) para [0039]	9
Y	WO 03028653 A2 (Taylor et al.) 10 April 2003 (10.04.2003) page 8, line 5, lines 15-20	11
Y	US 2012/0003321 A1 (Peng et al.) 05 January 2012 (05.01.2012) para [0003], [0004]	18

Further documents are listed in the continuation of Box C.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier application or patent but published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search
20 February 2015 (20.02.2015)

Date of mailing of the international search report
10 MAR 2015

Name and mailing address of the ISA/US
Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450
Facsimile No. 571-273-3201

Authorized officer:
Lee W. Young

PCT Helpdesk: 571-272-4300
PCT OSP: 571-272-7774

INTERNATIONAL SEARCH REPORT

international application no.

PCT/US 14/63846

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

- 1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

- 2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

- 3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
---please see supplemental box ---

- 1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
- 2. As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
- 3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
- 4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-21, 41, 42

Remark on Protest

- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- No protest accompanied the payment of additional search fees.

Box III: lack of unity

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I: claims 1-21 and 41-42, drawn to microparticles and their use.

Group II: Claims 22-40, drawn to a method of forming/delivering the microparticles

The inventions listed as Groups I through II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Special Technical Features

Group II requires a method of forming/delivering the microparticles, not required by group I

Shared technical Features

Groups I and II share the technical feature of microparticles comprising: a crosslinked gel; wherein the microparticles have a coefficient of variation in the size distribution of the microparticles of from about 0.03 to about 0.05 and wherein the microparticles have at least one dimension measuring from about 5 micro m to about 200 micro m.

However, these shared technical feature do not provide a contribution over the prior art because this shared technical feature is being obvious over US 2012/0076860 A1 to Trout et al. (hereafter 'Trout'). Trout teaches a Microparticles comprising: a crosslinked gel (table 2,.... crystallization with PEGDA microparticles of various mesh sizes....swollen cross-linked gels...); wherein the microparticles have at least one dimension measuring from about 5 micro m to about 200 micro m (claim 28), but does not specifically teach wherein the microparticles have a coefficient of variation in the size distribution of the microparticles of from about 0.03 to about 0.05. However, Trout does teach particles of various sizes (table 2). It would have been obvious to one of skill in the art to identify the coefficient of variation in the size distribution of the microparticles by routine experimentation.

Groups I-II, therefore, lack unity under PCT Rule 13.2, because they do not share a same or corresponding special technical feature providing a contribution over the prior art.